Chevy Chase Trust Holdings Inc. reduced its stake in shares of Allergan PLC (NYSE:AGN) by 2.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 331,102 shares of the company’s stock after selling 10,052 shares during the period. Chevy Chase Trust Holdings Inc. owned about 0.08% of Allergan PLC worth $76,256,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the stock. Clear Harbor Asset Management LLC bought a new stake in shares of Allergan PLC during the first quarter valued at about $668,000. Lowe Brockenbrough & Co. Inc. raised its stake in shares of Allergan PLC by 8.6% in the first quarter. Lowe Brockenbrough & Co. Inc. now owns 28,072 shares of the company’s stock valued at $7,524,000 after buying an additional 2,223 shares during the period. M&R Capital Management Inc. raised its stake in shares of Allergan PLC by 4.0% in the first quarter. M&R Capital Management Inc. now owns 24,303 shares of the company’s stock valued at $6,514,000 after buying an additional 936 shares during the period. Logan Capital Management Inc. raised its stake in shares of Allergan PLC by 1.2% in the first quarter. Logan Capital Management Inc. now owns 16,750 shares of the company’s stock valued at $4,490,000 after buying an additional 206 shares during the period. Finally, Lombard Odier Transatlantic Limited Partnership bought a new stake in shares of Allergan PLC during the first quarter valued at about $395,000. Hedge funds and other institutional investors own 85.20% of the company’s stock.

Institutional Ownership by Quarter for Allergan PLC (NYSE:AGN)

Allergan PLC (NYSE:AGN) opened at 191.78 on Friday. The stock has a market cap of $71.93 billion, a PE ratio of 5.38 and a beta of 1.08. Allergan PLC has a 12 month low of $186.34 and a 12 month high of $322.68. The stock has a 50 day moving average price of $223.79 and a 200-day moving average price of $234.52.

Allergan PLC (NYSE:AGN) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $3.32 earnings per share for the quarter, missing the Zacks’ consensus estimate of $3.65 by $0.33. Allergan PLC had a net margin of 93.74% and a return on equity of 7.26%. The firm earned $3.62 billion during the quarter, compared to the consensus estimate of $3.73 billion. During the same quarter last year, the firm posted $3.48 earnings per share. Allergan PLC’s revenue was up 4.4% compared to the same quarter last year. On average, analysts expect that Allergan PLC will post $13.37 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 28th. Investors of record on Tuesday, February 28th will be given a dividend of $0.70 per share. This represents a $2.80 dividend on an annualized basis and a yield of 1.46%. This is a positive change from Allergan PLC’s previous quarterly dividend of $0.05.

A number of analysts have issued reports on AGN shares. Vetr lowered shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 price target on the stock. in a research note on Monday, August 8th. JPMorgan Chase & Co. set a $325.00 price target on shares of Allergan PLC and gave the stock a “buy” rating in a research note on Friday, August 5th. Mizuho boosted their price target on shares of Allergan PLC from $232.00 to $246.00 and gave the stock a “neutral” rating in a research note on Friday, August 5th. RBC Capital Markets reiterated an “outperform” rating and set a $300.00 price target (down from $307.00) on shares of Allergan PLC in a research note on Wednesday, August 10th. Finally, Credit Suisse Group AG set a $322.00 price target on shares of Allergan PLC and gave the stock a “hold” rating in a research note on Wednesday, August 3rd. Six equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the company. Allergan PLC currently has a consensus rating of “Buy” and an average price target of $289.11.

In related news, CFO Maria Teresa Hilado acquired 1,422 shares of Allergan PLC stock in a transaction that occurred on Friday, November 11th. The stock was acquired at an average price of $210.64 per share, for a total transaction of $299,530.08. Following the transaction, the chief financial officer now directly owns 12,659 shares of the company’s stock, valued at approximately $2,666,491.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.27% of the company’s stock.

Allergan PLC Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

5 Day Chart for NYSE:AGN

Receive News & Stock Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related stocks with our FREE daily email newsletter.